精密治疗喘的药物:释放表观基因组和微生物组的潜力
Javier Perez-Garcia1, Andres Cardenas2, Fabian Lorenzo-Diaz3
1Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology, and Genetics, Universidad de La Laguna (ULL), La Laguna, Tenerife, Spain.
The Journal of allergy and clinical immunology
|June 21, 2024
概括
研究喘中的微生物组和表观基因组揭示了这些因素如何影响药物反应. 了解这些联系可以导致个性化医疗和新的喘治疗策略.
科学领域:
- 生物医学科学 生物医学科学
- 肺部病理学 肺部病理学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 喘是全球主要的健康问题,对患者造成重大负担.
- 患者对治疗的反应差异很大,需要对潜在机制进行进一步的研究.
- 遗传学,环境,表观遗传学和微生物组之间的相互作用可能解释这种异质性.
研究的目的:
- 对与喘治疗有关的微生物组和表观遗传学研究的现有文献进行批判性审查.
- 为了确定融合途径和潜在的生物标志物来预测药物反应.
- 讨论这个领域的挑战和未来的前景.
主要方法:
- 关于喘药理干预的表观遗传学和微生物组研究的文献综述.
- 专注于皮质类固醇,支气管扩展剂,阿齐思罗米,免疫疗法和梅波利祖马布.
- 免疫和炎症通路的分析,涉及微生物组与表观遗传的关联.
主要成果:
- 确立了喘治疗与人类表观基因组和微生物组之间的双向关系.
- 确定了这些关联的关键免疫和炎症途径 (例如IL-2,TNF-α,NF-κB).
- 突出了omics生物标志物的潜力,用于预测治疗反应和指导精准医学.
结论:
- 表观遗传学和微生物组研究提供了关于喘治疗反应的分子基础的见解.
- 涉及免疫和炎症反应的融合途径至关重要.
- 进一步评估omics生物标志物可以推进精准医学和喘治疗点的发现.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
270
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
270
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma: Pathogenesis and Management
384
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
384
COPD: Management Using Bronchodilators and Corticosteroids
195
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
195
Drugs Used in Lower Respiratory Disorders: Overview
412
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
412


